MTOR and neoplasm: These mutations are of prognostic and therapeutic value, as mutations of some genes, such as FGFR3 and TP53 appear to be tumor-stage dependent, whereas others, including mutations in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway, could be targets for possible future therapies [8].